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Abstract
Since the beginning of the 1990s, several telemedicine projects and studies 
focused on type 1 and type 2 diabetes have been developed, including very few elderly 
diabetic patients. Several of these projects specifically concerned elderly subjects 
(n = 4). Mainly, these projects and studies show that telemonitoring diabetes results 
in improved blood glucose control—a significant reduction in HbA1c, improved 
patient ownership of the disease, greater patient adherence to therapeutic and 
hygiene-dietary measures, positive impact on comorbidities (hypertension, weight, 
dyslipidemia), improved quality of life for patients, and at least good patient recep-
tivity and accountability. To date, the magnitude of its effects remains debatable, 
especially with the variation in patients’ characteristics (e.g., background, ability for 
self-management, medical condition), sample selection, and approach for treatment 
of control groups. Over the last 5 years, numerous telemedicine projects based on 
connected objects and new information and communication technologies (ICT) (ele-
ments defining telemedicine 2.0) have emerged or are still under development.
Keywords: elderly patient, telemedicine, telemonitoring, diabetes,  
artificial intelligence, information and communication technology, Web,  
heart failure, chronic disease
1. Introduction
Intensive glucose control has been shown to delay or prevent the development 
of micro- and macrovascular complications related to diabetes, even in elderly 
diabetic patients. However, it is estimated that 43.2–55.6% of diabetic patients 
with type 2 diabetes do not meet the reference target for glycemic control (hemo-
globin A1c [HbA1c] < 7.0%) [1]. Factors that may contribute to suboptimal blood 
glucose (BG) control include inadequate home BG monitoring, nonadherence 
or noncompliance with medications or lifestyle changes (nutrition and sport), 
suboptimal patient education about the disease, and limited access to health pro-
fessionals [1–3]. In the absence of timely and accurate data on home BG values, 
healthcare professionals may be reluctant, rightly so, to aggressively intensify 
oral hypoglycemic agents or insulin treatments for fear of hypoglycemia [4]. 
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This is particularly true in the elderly, where hypoglycemia can have dramatic 
consequences, such as myocardial infarction (MI), falls, etc. These patients have 
a high mortality rate, with 20% of deaths occurring within 5 years after the first 
cardiovascular event. In this context, patients are often hospitalized, with pro-
longed and iterative hospitalization [2].
In practice, the main causes of diabetes required medical intervention are related 
to the following: nontherapeutic adherence and compliance, poor nutrition, and 
poor adherence to prescribed lifestyle changes and therapy, the decompensation 
of diabetic comorbidities and macrovascular complication, and community-based 
infections [2]. In this context, telemedicine may be an effective approach in solving 
problems of education, compliance, and monitoring and provider access [2, 5]. BG 
control could be safely improved by basing drug changes on home BG readings and 
transmitting them in near real time to providers, particularly in elderlies. In this set-
ting, telemedicine may also be an effective solution to monitor the complications of 
the diabetes, especially macrovascular complications (e.g., MI, heart failure [HF], 
etc.) and comorbidities (e.g., arterial hypertension).
In this article, we review the literature in the field of telemonitoring (remote 
monitoring) of diabetic patients, with a focus on elderly diabetic patients.
2.  First-generation telemedicine projects and studies in the field of 
diabetes
Since the early 1990s to the end of 2010, numerous telemedicine projects and 
studies have been developed in the field of diabetes [6–27]. Practically all of them have 
investigated telemonitoring or telephone follow-up (defined terms in Table 1), especially 
to monitor BG levels. For the majority of them, they were conducted on specific popu-
lation of poor controlled type 1 and type 2 diabetic patients,  including very few elderly 
diabetic patients. Several of these projects include specifically elderly diabetic patients 
(< 80 years old) (n = 1) [21, 27]. Mainly these projects have been developed in children 
and young people (n = 3), young or mild-age patients with intensified therapy (n = 2), 
young or mild-age patients under insulin pump therapy (n = 1), and patients with 
complicated or complex diabetes, including several elderly patients (n = 2) [6–27].
To our knowledge, to date, no project has been published on tele-consultation and 
teleexpertise (defined terms in Table 1) in the area of diabetes domain, as defined 
under European or French legislation [28]. Several of such projects have been 
developed, but no formal scientific conclusions are currently available about the 
usefulness of these telemedicine technologies [29].
It is worth bearing in mind that these projects and studies [6–27], particu-
larly the earlier ones, more closely resembled as a telephone follow-up with care 
providers (such as a nurse) traveling to the diabetic patient’s home rather than 
telemedicine use as we think of it nowadays with nonintrusive, automated, smart 
telemonitoring employing remote sensors via modern communication technology 
(e.g., smartphone) or even artificial intelligence (AI) (Table 1) [29]. Thus, they 
characterize in our opinion first-generation telemedicine projects and studies.
Using PubMed database and Google Scholar, we have identified more than 20 
reports of first-generation telemonitoring studies in the field of diabetes, including 
type 1 and type 2 diabetic patients, involving the upload and direct transmission of 
BG data by diabetic patients to providers via cellular telephone, telephone landline, 
or a Web-based program [6–27]. The results of these studies were mixed, perhaps 
because many studies did not target diabetic patients with poor baseline BG control 
or the interval between glucose transmission and follow-up was delayed or unspeci-
fied or mainly with no therapeutic intervention (therapeutic inertia). None of these 
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reports evaluated the intensity of intervention required to sustain achieved reduc-
tions in HbA1c after the implementation of home telemonitoring.
As with CHF, the results of these first-generation telemedicine projects differed 
from study to study, with fairly inconclusive results as to their potential clinical 
benefits in terms of balancing diabetes and the associated metabolic problems, 
re-hospitalization, and decreased morbidity or mortality, particularly regarding the 
statistical significance of the results [29, 30]. As a consequence, experts have shared 
now widely divergent opinions on the actual utility of telemedicine in diabetic 
patient management [29, 30].
To our knowledge, it should be emphasized that the first-generation studies and 
trials on telemedicine in diabetic patients were at times conducted with [29]:
• Inappropriate methodologies, involving unsuitable patient groups (such as 
well-balanced diabetic patients, diabetic patients without any complication) 
of small-sized patient samples and with very short follow-up periods (between 
3 months and 1 year)
• Not well-structured follow-up organization, with nonspecialized staff to 
alarms, or without any association of patients’ general practitioners, specialists 
of diabetes management, or endocrinologists nor any optimized management 
process or algorithm
• Several alarms arising too late, without therapeutic response (no specified 
therapeutic protocol available)
• No associated educational programs
• The absence of a human interface or contact between the telemedicine solution 
and the patients
Moreover, most of these studies were only based on glycemic control, without 
including other warning or monitoring parameters related to comorbidities or dia-
betic complication (e.g., tensiometer, heart rate, balance), with an underutilization 
-Telemedicine: provision of remote patient care and consultation using telecommunication technologies.
-Telemonitoring: this telemedicine practice allows a healthcare professional to remotely interpret the data 
necessary for the patient’s medical follow-up in order to make decisions about his / her care. Remote data 
collection from a patient through a connected device or questionnaires to monitor his/her vital parameters 
and symptoms at home on a daily basis.
-Teleexpertise: this practice of telemedicine consists, for a medical professional, to seek the opinion of one 
or more medical professional experts regarding elements of the patient’s medical file. Remote seeking by a 
health professional of a second medical opinion via sending of images (scanner, X-ray, eye fundus, etc.) and 
sometimes exchange by Internet-based videoconference.
-Teleconsultation: this telemedicine practice allows a medical professional to hold a consultation with a 
patient remotely. In the context of a teleconsultation, the patient can have at his/her side a health professional 
assisting the remote professional as well as a psychologist. Second opinion consultation by specialist.
-Telemedicine 2.0: over the last decade, the Internet has become increasingly popular and is now an 
important part of our daily life. The use of “Web 2.0” technologies in health/medicine care or in telemedicine 
is referred to as “Health 2.0” or “Medicine 2.0,” and “telemedicine 2.0.”
-Artificial intelligence: this concept makes it possible for machines to learn from experience, adjust to new 
inputs and perform human-like tasks. These processes include learning (the acquisition of information and 
rules for using the information), reasoning (using the rules to reach approximate or definite conclusions) and 
self-correction. Particular applications of AI include expert systems, speech recognition, and machine vision.
Table 1. 
Glossary of terms and definitions in the field of telemedicine [29].
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Figure 1. 
Results of IDEAtel trial (n = 1665 diabetic elderly patients) (adapted from [21, 27]).
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of the deployed device [29, 30]. Thus in our opinion, these facts explain that the 
demonstration of any benefits with these first-generation studies was “illusory,” in 
particular in terms of statistical significance.
Besides these medical considerations, it is worth noting that an economical 
aspect must be investigated and consolidated in future telemedicine projects to 
promote the development of telemedicine in diabetes and legitimize it, especially in 
regard of the budgetary constraints affecting insurance and mutual health insur-
ance companies. Things are less advanced than in the field of chronic heart failure 
telemonitoring [29]. To our knowledge, only Biermann’s study is dedicated to this 
theme of economical aspect [11].
To date, none of the learned societies (e.g., American Diabetes Association 
[ADA], European Society of Diabetes [ESD]) involved in the topic of diabetes has, to 
our knowledge, made any formal recommendation as to whether or not telemedi-
cine is of benefit to type 1 or type 2 diabetic patients. This is not the case in the set-
ting of CHF, where factual data and medico-economic studies are more numerous, 
better documented, and consolidated (more mature field) [29]. In fact, the 2016 
European Society of Cardiology (ESC) guidelines for the diagnosis and treatment of 
acute and chronic heart failure have recommended telemonitoring of heart failure 
patients with a recommendation grade of IIb and level of evidence B [31].
In the setting of diabetic patients, Shea et al. have conducted the first telemedicine 
study specifically dedicated to “elderly” diabetic patients (aged 55 years or greater) [21, 
27]. It is a randomized, controlled trial comparing telemedicine case management to 
usual care, with blinding of those obtaining outcome data, in 1665 Medicare recipients 
with diabetes. In the intervention group (n = 844), mean HbA1c improved over 1 year 
from 7.35 to 6.97% and from 8.35 to 7.42% in the subgroup with baseline HbA1c ≥ 7% 
(n = 353) [21]. In the usual care group (n = 821), mean HbA1c improved over 1 year 
from 7.42 to 7.17%. Adjusted net reductions (1 year minus baseline mean values in 
each group, compared between groups) favoring the intervention were as follows (all 
principal criteria): HbA1c, 0.18% (p = 0.006); systolic and diastolic blood pressure, 3.4 
(p = 0.001) and 1.9 mmHg (p < 0.001); and LDL cholesterol, 9.5 mg/dL (p < 0.001) 
(Figure 1). In the subgroup with baseline HbA1c ≥ 7%, net adjusted reduction in 
HbA1c favoring the intervention group was 0.32% (p = 0.002). Mean LDL cholesterol 
level in the intervention group at 1 year was 95.7 mg/dL. Mortality was not different 
between the groups, although power was limited. There were 176 deaths in the inter-
vention group and 169 in the usual care group (hazard ratio 1.01 [0.82, 1.24]).
3.  Second-generation telemedicine projects and studies in the field of 
diabetes
Over the last 10 years, second-generation telemedicine projects and studies have 
been developed in the setting of diabetes management, especially in the setting of 
telemonitoring [32–38], as defined in Table 1. These projects and studies have main 
objectives to evaluate the use of technology to implement medical and cost-effective 
healthcare management on a large scale for diabetes management. These projects 
include very few elderly patients. One project, the DiaTel study, was dedicated 
to elderly diabetic patients (<80 years old) [32]. Compared to the aforementioned 
project, most of the second-generation projects related to diabetes telemonitoring (for 
type 1 diabetic patients, n = 1; for type 2, n = 5) incorporate the following [32–38]:
• Self-administered medical questionnaires or forms on symptoms and signs of 
diabetes decompensation and BG levels
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• Tools for medical education, particularly disease self-appropriation, food 
hygiene, and physical activity
• Tools for patient motivation
• Tools for therapeutic and hygiene observance
• Tool to remote comorbidities (e.g., arterial hypertension, obesity, 
dyslipidemia)
• Tools for interaction between the patient and healthcare professionals like 
telephone support centers, tablets, and Websites
3.1 The DiaTel study
The DiaTel study compared the short-term efficacy of home telemonitoring 
coupled with active medication management by a nurse practitioner with a monthly 
care coordination telephone call on glycemic control in veterans with type 2 diabetes 
[32]. The included patients were taking oral hypoglycemic agents and/or insulin for 
≥1 year and had HbA1c ≥ 7.5%). Approximately one-third of the participants in both 
groups were aged 65 years. At enrollment, the patients were randomly assigned to 
either active care management (AMC) with home telemonitoring (HT) (ACM + HT 
group, n = 73) or a monthly care coordination telephone call (CC group, n = 77) [32]. 
Both groups received monthly calls for DM education and self-management review. 
ACM + HT group participants transmitted BG, blood pressure (BP), and weight to 
a nurse practitioner; the nurse practitioner adjusted medications for glucose, BP, 
and lipid control based on established ADA targets. Baseline characteristics of the 
patients in the DiaTel study were similar in both groups, with mean HbA1c of 9.4% 
in the CC group vs. 9.6% in ACM + HT group [32, 33]. Compared with the CC group, 
the ACM + HT group demonstrated significantly larger decreases in HbA1c (princi-
pal criterion) at 3 months (1.7 vs. 0.7%) and 6 months (1.7 vs. 0.8%; p < 0.001 for 
each), with most improvement occurring by 3 months (Figure 2).
3.2 The Utah Remote Monitoring Project
The Utah Remote Monitoring Project was a nonrandomized prospective obser-
vational pre- and post-intervention study [34]. The included patients were patients 
with uncontrolled type 2 diabetes and/or arterial hypertension. They have been 
enrolled from four rural and two urban primary care clinics and one urban stroke 
center participated in a telemonitoring program (n = 109). The primary clinical 
outcome measures were changes in HbA1c and BP. Other outcomes included fasting 
lipids, weight, patient engagement, diabetes knowledge, arterial hypertension 
knowledge, medication adherence, and patient perceptions of the usefulness of 
the telemonitoring program. The patients were randomized in two groups on 
telemonitoring delivery methods [34]. The first was a remote monitoring device for 
BP and heart rate. Patients used their own glucose meters to measure BG and were 
provided with an electronic digital scale to measure their weight. The device was 
programmed to sound an alarm at a pre-specified patient-referred time to prompt 
the patient to initiate a telemonitoring session. Patients were asked to enter data 
several times during the week. The device was programmed to ask how patients 
were feeling that day and whether they had taken their medications and then 
receive a prompt to take the measures. After, the patient received a series of educa-
tion messages, focused on teaching patients about their diseases (diabetes, arterial 
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hypertension) and associated comorbidities. The second telemonitoring delivery 
method is the use of an interactive voice response (IVR) system. Patients were 
provided with a BP monitor and electronic digital scales, but they used their own 
BG meter. The patients have to use the same process described above, but received 
a call from the telemonitoring IVR service at a pre-specified. Medical providers 
were contacted either via a note in the electronic medical record (or immediately 
if there was a concern, in person or by telephone) if there was an out-of-range 
value (decided by individual providers or clinics as a value that was high or low). 
In this study, the mean HbA1c (principal criterion) decreased: 9.73% at baseline vs. 
Figure 2. 
Results of DiaTel study (n = 150 diabetic elderly patients) (adapted from [32]).
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7.81% at the end of the program (p < 0.0001) [34]. Systolic BP (principal criterion) 
also declined significantly: 130.7 mmHg at baseline vs. 122.9 mmHg at the end 
(p = 0.0001). Low-density lipoprotein content decreased significantly: 103.9 mg/dL 
at baseline vs. 93.7 mg/dL at the end (p = 0.0263). Knowledge of diabetes and arte-
rial hypertension increased significantly (p < 0.001 for both). Patient engagement 
and medication adherence also improved, but not significantly. Per questionnaires 
at study end, patients felt the telemonitoring program was useful.
3.3  Randomized trial on home telemonitoring for the management of metabolic 
and cardiovascular risk in patients with type 2 diabetes
This study evaluated whether a home telehealth (HT) system can improve meta-
bolic control and overall cardiovascular risk in individuals with type 2 diabetes, 
compared with usual practice [35]. This study was a randomized, parallel-group, 
open-label, multicenter study conducted in general practice (29 general practitio-
ners) including 302 patients, with a follow-up of 12 months. The HT system (for the 
telemedicine group of diabetic patients, n = 153) offers to the patient the  possibility 
to monitor body weight, BG values, and BP values, associated with remote edu-
cational support and feedback to the general practitioner [35]. The use of the HT 
system was associated with a statistically significant reduction in HbA1c levels 
(principal criterion) compared with the control group: estimated mean difference 
of 0.33 ± 0.1 (p = 0.001) [35]. No difference was documented for body weight, BP, 
and lipid profile (all principal criteria). The proportion of patients reaching the 
target of HbA1c (HbA1c < 7.0%) was higher in the HT group than in the control 
group after 6 months, 33.0 vs. 18.7% (p = 0.009), and 12 months, 28.1 vs. 18.5% 
(p = 0.07). As for quality of life (evaluated with the 36-item short-form health 
survey), significant differences in favor of the HT group were detected as for physi-
cal functioning (p = 0.01) and mental health (p = 0.005). On an economic level, a 
lower number of specialist visits was reported in the telemedicine group: incidence 
rate ratio of 0.72 (95% confidence interval, 0.51–1.01; p = 0.06).
3.4 Study assessed the utility and cost-effectiveness of an automated Diabetes 
Remote Monitoring and Management System (DRMS)
This study assessed the utility and cost-effectiveness of an automated Diabetes 
Remote Monitoring and Management System (DRMS) in glycemic control versus usual 
care [36]. In this randomized, controlled study, patients with uncontrolled diabetes on 
insulin were randomized to use the DRMS or usual care. Participants in both groups 
were followed up for 6 months and had three clinic visits during the study period 
(at 0, 3, and 6 months [35]). The DRMS used text messages or phone calls to remind 
patients to test their BG and to report results via an automated system, with no human 
interaction unless a patient had severely high or low BG. The DRMS made adjustments 
to insulin dose(s) based on validated algorithms. Participants reported medication 
adherence through the Morisky Medication Adherence Scale-8, and diabetes-specific 
quality of life through the diabetes daily quality-of-life questionnaire. A cost-effective-
ness analysis was conducted based on the estimated overall costs of DRMS and usual 
care. A total of 98 diabetic patients (60% of female) treated with insulin therapy were 
enrolled [36]. The mean age of the patients was 59 years. At the end, 87 patients (89%) 
have completed the follow-up. HbA1c was similar between the DRMS and control 
groups at 3 months, 7.60 vs. 8.10%, and at 6 months, 8.10 vs. 7.90% (p = ns) (principal 
criterion) [42]. Changes from baseline to 6 months were not statistically significant for 
self-reported medication adherence and diabetes-specific quality of life, except for the 
Daily Quality of Life-Social/Vocational Concerns subscale score (p = 0.04).
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3.5 The Telescot Diabetes Pragmatic Multicenter Randomized Controlled Trial
The Telescot Diabetes is a randomized, parallel, investigator-blind controlled 
trial with centralized randomization in family practices in four regions of the 
United Kingdom [37]. This study included 321 patients with relatively well-
controlled type 2 diabetes, with an HbA1c > 7.46%. In Telescot Diabetes, 160 
people were randomized to the intervention group and 161 to the usual care group 
[37]. The supported telemonitoring intervention involved self-measurement and 
transmission to a secure Website of twice-weekly morning and evening glucose for 
review by family practice clinicians who were not blinded to allocation group. The 
control group received usual care, with at least annual review and more frequent 
reviews for people with poor glycemic or BP control. HbA1c assessed at ninth month 
was the primary outcome. The mean (SD) HbA1c at follow-up was 7.92% in the 
intervention group vs. 8.36% in the usual care group [37]. For primary analysis, 
adjusted mean HbA1c was 0.51% lower (95% CI 0.22% to 0.81%, (principal crite-
rion) (p = 0.0007)). For secondary analyses, adjusted mean ambulatory systolic BP 
was 3.06 mmHg lower (95% CI 0.56–5.56 mmHg, p = 0.017) and mean ambulatory 
diastolic BP was 2.17 mmHg lower (95% CI 0.62–3.72, p = 0.006) among people 
in the intervention group when compared with usual care after adjustment. No 
significant differences were identified between groups in weight, treatment pat-
tern, adherence to medication, or quality of life in secondary analyses. During the 
study, the number of telephone calls was greater between nurses and patients in the 
intervention compared with control group: rate ratio of 7.50 (95% CI 4.45–12.65, 
p < 0.0001), but no other significant differences between groups in the use of 
health services were identified between groups.
3.6 Educ@dom
Educ@dom is a multicenter, randomized, controlled, prospective study [38]. 
The primary objective of this study is to compare the efficacy of telemonitoring to 
standard monitoring in terms of changes in HbA1c after a 1-year follow-up period. 
The secondary objectives are clinical (changes in knowledge, physical activity, 
weight, etc.) and medical-economic. The Educ@dom study included 282 patients, 
141 patients in each arm [38]. For patients in the intervention group, the device will 
be given to them for 1 year and then withdrawn during the second year of follow-
up. The anticipated benefits of this research are an improvement in BG manage-
ment in patients with type 2 diabetes by improving their lifestyle while rationalizing 
recourse to consultations in order to reduce the incidence of complications and cost 
in the long term. The results of this study are expected in 2019–2020.
4. New-generation projects and studies in diabetes
Over the last 5 years, new-generation telemedicine projects and studies have 
emerged in the setting of chronic diseases setting, especially in the setting of 
chronic heart failure, chronic obstructive pulmonary diseases, and type 1 and type 
2 diabetes [29, 39–42]. They support transmission and remote interpretation of 
patients’ data for follow-up and preventive interventions. These projects and  
studies have for main objectives to evaluate the use of technology to implement 
medical and cost-effective healthcare management on a large scale for diabetes 
management. Using PubMed database and Google Scholar, we have identified three 
of such projects and studies in the field of diabetes management: Telemonitoring 
and Health Counseling for Self-Management Support from Lindberg et al., 
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TELESAGE, and DIABETe [39–42]. All these projects include elderly diabetic 
patients. Of note for the first time, one the telemedicine projects developed for 
chronic diseases management, the TIM-HF2 study [43], has recently demonstrated 
the usefulness of telemedicine in chronic heart failure, with statistical significance, 
in a prospective randomized study (the gold standard of evidence-based medicine 
[EBM]).
Between August 13, 2013, and May 12, 2017, 1571 patients (mean age of 70 years) 
were included in the TIM-HF2 study and randomly assigned to remote patient 
management (n = 796) or standard care (n = 775) [43]. At baseline, all patients 
exhibited a left ventricular ejection fraction of <45% and NYHA II or III while 
receiving treatment with diuretics. In TIM-HF2 study, the percentage of days lost 
due to unplanned cardiovascular hospital admissions and all-cause death was 4.88% 
(95% CI 4.55–5.23) in the remote patient management group vs. 6.64% (6.19–7.13) 
in the standard care group (ratio 0.80, 95% CI: 0.65–1) (p = 0.0460). The all-cause 
death rate was 7.86 (95% CI: 6.14–10.10) per 100 person-years of follow-up in the 
remote patient management group vs. 11.34 (95% CI: 9.21–13.95) per 100 person-
years of follow-up in the standard care group (hazard ratio [HR] 0.70, 95% CI: 
0.5–0.96) (p = 0.0280) (Figure 3). Cardiovascular mortality did not significantly 
differ between both groups (HR 0.671, 95% CI: 0.45–1.01; p = 0.056).
The TIM-HF2 study utilized a noninvasive, multiparameter telemonitor-
ing system installed in the patient’s home, comprising a three-channel ECG, 
BP-monitoring device, and weighing scales, by means of which the information 
was transferred remotely [43]. Patients received a mobile phone in order to contact 
the telemedical center in case of emergency. Patients were likewise followed via 
monthly phone interviews. For this TIM-HF2 care strategy, the key component 
was a well-structured telemedical center with physicians and HF nurses (center of 
coordination), available 24 hours a day and every day a week, able to act promptly 
according to the individual patient risk profile. The actions taken by the telemedical 
center staff included changes in medication and admission to hospital, as needed, in 
addition to educational activities.
In this setting, we believe that, thanks to technological innovations in connected 
health-monitoring devices, the telemonitoring of type 2 diabetic patients using 
Figure 3. 
TIM-HF2 trial. Rate of cumulative events in patients randomly assigned to remote patient management 
(n = 796) or usual care (n = 775) (adapted from [43]).
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therapeutic educational tools is likely to help them adapt to their treatment and 
lifestyle habits and therefore improve BG management [29].
These new-generation telemedicine projects in diabetes (Telemonitoring and 
Health Counseling for Self-Management Support from Lindberg et al., TELESAGE, 
DIABETe) [39–42] are often known as telemedicine 2.0 projects, given that they all 
utilize new information and communication technologies (ICT) and the Web (tools 
for the e-Health 2.0) (as defined in Table 1) [44].
Most projects and studies rely on the standard connected tools for  monitoring 
type 1 and type 2 diabetes, such as glucose meters, BP, heart rate monitors, 
weighing scales, and pulse oximeters, which relay the collected information via 
Bluetooth, 3G, or 4G [29, 39–42]. Several projects also include continuous glyce-
mic monitoring solution and often a video-call [29, 30]. Several of these telemedi-
cine projects use machine learning, also called artificial intelligence (AI), in order 
to be able to:
• Adjust the BG level to the patient’s activity (software Diabeo™ [see below]) 
[40, 41].
• Predict patient risks of diabetes decompensation [42, 45]. In this later situation, 
the cloud-based software aggregates, cleans, and analyzes patient data to allow 
for identifying patterns that may indicate potential risks and provide predictive 
insights on healthcare outcomes, as the software MyPredi™ (see below) [29, 42].
In the setting of chronic diseases, as in chronic heart disease or in diabetes, 
 several informatics solutions or tools have been developed and used, such as 
artificial neural network (ANN) algorithms, data mining software, and ontology 
[45, 46]. In this context of AI, three clinical datasets are of particular interest: (1) 
patients’ phenotype; (2) patients’ electronic medical records containing physicians’ 
notes, laboratory test results, as well as other information on diseases, treatments, 
and epidemiology that may be of interest for association studies and predictive 
modeling on prognosis and drug responses; and (3) literature knowledge including 
rules on diabetes management [46].
Besides these tools, it must be emphasized that diabetes telemonitoring may use, 
as for CHF telemonitoring, implantable invasive devices that send either sporadi-
cally or continuously data to the receiving physician (automatic telemonitoring) 
(outside the scope of this paper) [30]. In management of diabetes, implantable 
telemonitoring devices for multiparameters including mainly BG-insulin levels 
monitoring have recently proven to be an effective approach.
4.1  Telemonitoring and Health Counseling for Self-Management Support of 
Patients with Type 2 Diabetes
The objective of this study (Telemonitoring and Health Counseling for Self-
Management Support) was to investigate whether the introduction of a health  
technology-supported self-management program involving telemonitoring and 
health counseling had beneficial effects on HbA1c, other clinical variables (weight, 
body mass index, BP, blood lipid profile), and health-related quality of life (HRQoL), 
as measured using the short-form health survey (SF-36) version 2 in patients with 
type 2 diabetes [39]. This was a pragmatic randomized controlled trial of patients 
with type 2 diabetes. Both the control (n = 79) and intervention groups (n = 87) 
received usual care [39]. The intervention group also participated in additional health 
promotion activities with the use of the Prescribed Healthcare Web application 
for self-monitoring of BG and BP. About every second month or when needed, the 
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general practitioner or the DM nurse reviewed the results and the healthcare activity 
plan. Analyses of the data showed that there were no significant differences between 
the groups in the primary outcome HbA1c level (p = 0.33) and in the secondary 
outcome HRQoL as measured using SF-36 [39]. A total of 80% of the patients in the 
intervention group at the baseline and 98% of the responders after 19-month inter-
vention were familiar with using a personal computer (p = 0.001). After 19 months, 
no responders reported significantly poorer mental health in social functioning and 
role emotional subscales on the SF-36 (p = 0.03 and p = 0.01, respectively).
4.2 TELESAGE study
TELESAGE (Suivi A Grande Echelle d’une population de diabétiques de type 1 et de 
type 2 sous schéma insulinique basal bolus par la TELEmédecine [large-scale follow-up of 
a population of type 1 and type 2 diabetics under basal insulin regimen bolus by tele-
medicine]) is a 6-month open-label parallel-group, multicenter study, including adult 
patients (n = 180) with type 1 diabetes (>1 year), on a basal-bolus insulin regimen 
(> 6 months), with HbA1c ≥ 8%, conducted in approximately 100 centers in France 
[40, 41]. These type 1 diabetic patients were randomized to usual quarterly follow-up 
(G1), home use of a smartphone recommending insulin doses (Diabeo™ software) 
with quarterly visits (G2), or the use of the smartphone with short teleconsultations 
every 2 weeks but no visit until point end (G3) [40, 41]. The primary objective of 
TELESAGE will be to investigate the effect of the Diabeo™ telemedicine system 
versus usual follow-up, with respect to improvements in the HbA1c levels (princi-
pal criterion) of diabetic patients with poorly controlled basal-bolus insulin levels 
(n = 696). The study will compare a control group (group 1 [G1], usual follow-up) 
with two Diabeo™ telemedicine systems: (1) physician-assisted telemedicine (group 2 
[G2]) and (2) nurse-assisted telemonitoring and teleconsultations by a diabetolo-
gist’s task delegation (group 3 [G3]). At 6 months, the mean HbA1c level is as follows: 
8.41 ± 1.04% in G3 vs. 8.63 ± 1.07% in G2 vs. 9.10 ± 1.16% in G1 (p = 0.0019 for G1–G3 
comparison) (Figure 4) [40, 41]. The Diabeo™ system gave a 0.91% (0.60–1.21) 
improvement in HbA1c over controls and a 0.67% (0.35–0.99) reduction when used 
without teleconsultation. There was no difference in the frequency of hypoglycemic 
episodes or in medical time spent for hospital or telephone consultations. However, 
patients in G1 and G2 spent nearly 5 h more than G3 patients attending hospital visits.
4.3 DIABETe project
The DIABETe project is scheduled to experiment a telemonitoring solution for 
at-home monitoring of type 1 and type 2 diabetic patients [29, 42]. The DIABETe 
telemonitoring project, conducted in Strasbourg (France), falls under the “tele-
medicine 2.0” category (as described above) [29, 44]. It has been developed and 
designed to optimize home monitoring of diabetic patients by detecting, via a 
telemonitoring 2.0 platform, situations with a risk of decompensation of diabetes 
and its complications (e.g., MI or CHF), the latter ultimately leading to hospitaliza-
tion [29, 42]. The AI of the DIABETe platform (MyPredi™) automatically generates 
indicators of health status deterioration, i.e., warning alerts for any chronic disease 
worsening, particularly diabetes, its macrovascular complications, and cardiovascu-
lar comorbidities (e.g., arterial hypertension, chronic heart failure). For the patient, 
these situations may lead to hospitalization if not treated appropriately. To our 
knowledge, this is one of the first projects that use AI in addition to ICT. The plat-
form comprises connected nonintrusive medical sensors (Figure 5), a touchscreen 
tablet connected by Wi-Fi, and a router or 3G/4G, rendering it possible to interact 
with the patient and provide education on treatment, diet, and lifestyle [29, 42].
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The system (Figure 6) involves a server that hosts the patient’s data and a secure 
Internet portal to which the patient and hospital- and nonhospital-based healthcare 
professionals can connect (Figure 7) [29, 42].
DIABETe is based on a smart system comprising an inference engine and a medical 
ontology for personalized synchronous or asynchronous analysis of data specific to each 
patient and, if necessary, the sending of an AI-generated alert (MyPredi™) [29, 42].
DIABETe is run by a group bringing together the Strasbourg University Hospital 
(Hôpitaux Universitaires de Strasbourg), East Regional Health Agency (Agence 
Figure 4. 
Efficacy of the software Diabeo™ (adapted from [40]).
Figure 5. 
DIABETe’s connected nonintrusive medical sensors.
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Régionale de Santé du Grand Est), Bas-Rhin branch of France’s National Health 
Insurance (Caisse Primaire d’Assurance du Bas-Rhin), and Predimed Technology 
start-up [29, 42]. This project is likely allowing an in-depth study to be carried out 
designed to improve diagnosis by machine learning and detect abnormalities in 
diabetic patients at an early time point.
The telemonitoring platform used in DIABETe was first validated in a mono-
centric study conducted in the Strasbourg University Hospital, carried out as part 
of the E-Care project, primarily focused on the problem of CHF [47, 48]. Between 
February 2014 and April 2015, 175 elderly patients (mean age of 72 years) were 
included into the E-care project; 30% of these patients suffered from type 2 dia-
betes. During this period, the telemonitoring platform was used on a daily basis by 
patients and healthcare professionals, according to a defined protocol of use specific 
to each patient. During the study, 1500 measurements were taken, generating 700 
alerts in 68 patients. One hundred seven subjects (61.1%) had no alerts upon follow-
up. Analysis of the warning alerts in the 68 other patients showed that MyPredi™ 
Figure 7. 
DIABETe’s Internet portal.
Figure 6. 
DIABETe’s platform.
15
State of Art of Telemonitoring in Patients with Diabetes Mellitus, with a Focus on Elderly Patients
DOI: http://dx.doi.org/10.5772/intechopen.83384
detected any worsening of the “patient’s health,” with a sensitivity, specificity, as 
well as positive and negative predictive values of 100, 30, 89, and 100%, respec-
tively. In this experimentation, both the healthcare professionals and patients, even 
the frailest, used the E-care system without difficulty until the end of the study.
The patients included in the DIABETe project were real-life type 1 and type 2 
diabetic patients (n = 100) with (i) a “very high cardiovascular risk,” when pre-
senting a personal history of myocardial infarction or stroke, limb amputation, or 
cardiomyopathy and (ii) an “intensive” insulin therapy, with at least three injections 
per day or pump administration while offering them a personalized follow-up and 
education about their illness and its management [29, 42]. To date, several patients 
have been included. The results of this project are expected in late 2019–early 2020.
The DIABETe project is based on an intelligent platform that likely assists 
healthcare professionals by automatically processing the information obtained 
from nonintrusive medical sensors (BG meter, BP monitor, actimeter, connected 
scale, etc.) as well as the subjective information provided by the patient himself 
(questionnaires) and his/her behavior (compliance), enabling it to detect and 
report, at an early time, these situations at risk of hospitalization [29, 42]. Patient- 
and situation-adapted therapeutic education tools will be made available to the 
individual, and communication with the subject will likely occur via a touch pad. 
Alerts indicating a deterioration of the patient’s condition will be generated by AI 
(new software version of MyPredi™ adapted for the management of diabetes) and 
transmitted to the health professionals in charge of the patient. The healthcare pro-
fessional can thus anticipate the decompensation and initiate appropriate measures 
outside the emergency setting. An intermediate analysis is planned after the first 30 
patients, possibly to set up a coordination cell with a nurse, as part of a delegation 
of tasks, as in TIM-HF2 [43]. Medical data can likewise be shared among health 
professionals, being part of a city-hospital network. Ultimately, an improvement in 
the patients’ quality of life is to be expected.
DIABETe does not compete with Diabeo™ or other expert systems aimed at 
optimizing the glycemic balance, which is per se the main objective of diabetes 
management [41]. The DIABETe project focuses on the “global” management of 
diabetic patients through the detection of situations at risk of hospitalization: 
infection, cardiac decompensation, diabetic foot, as well as hypoglycemia and 
hyperglycemia episodes, potentially leading to hospitalizations [29, 42]. Regarding 
the remote monitoring platform used in DIABETe, an integration of or interfacing 
with expert systems such as Diabeo™ [41, 42] appears possible.
5. Perspectives regarding new developments in telemedicine
In the future, telemedicine projects will have to address some of today’s medical 
issues (challenge for “tomorrow telemedicine”) [29, 30]. Thus, the new solutions 
of telemedicine have to take into account the coexistence in the same individual of 
numerous chronic pathologies (e.g., diabetes, CHF, chronic obstructive pulmonary 
disease, chronic renal failure, etc.) and comorbidities (high BP, dyslipidemia, etc.). 
They have to offer complete and “global” management, including both social and 
medical dimensions. They have to resolve the specificities of elderly patients: no 
appetite for new technologies and new uses and their main problems (e.g., falls, 
malnutrition, mild cognitive impairment, etc.).
In this setting, the new developments in telemedicine are also to resolve the 
multiplicity of health professionals working with the same patient and the multi-
plicity of medical organizations (e.g., with or without human resources, telemedi-
cal center, etc.) [29, 30]. Today, the logistical obstacles to the implementation of 
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telehealth are significant, as many health systems are not yet designed to integrate 
these technologies into existing information systems. It is therefore necessary to 
plan now for an interfacing of computer systems and the integration of future 
telemedicine solutions.
Considering the current problems of access to healthcare professionals, the 
new telemedicine solutions must be able to structure the patients’ care pathways, a 
major medical topic that should interest our governments and authorities [28, 29]. 
Likewise, the E-care and DIABETe projects provide a means for healthcare profes-
sionals to exchange with each other, thereby facilitating patient access to medical 
resources. In this context, future research must also focus on the accessibility and 
practicality of telemedicine interventions.
Importantly, reimbursement remains a major concern and a barrier (“glass 
 ceiling”). In fact, the healthcare delivered by telehealth is not covered by traditional 
fee-for-service payment models (e.g., in France, where all diabetic patients benefit 
from an integral treatment of their health expenses) [29]. The growth of value-based 
payment models may, however, provide incentives to implement telehealth as a strategy 
to provide high-quality, cost-effective, and coordinated care [29]. At country levels, 
variations in practice laws, restrictions on how telehealth can be delivered, and which 
patients should receive these services limit telemedicine’s applicability as well [30].
Thus, to document the efficacy on the new telemedicine solutions, the future 
studies should integrate others objectives like potential targets to meet the needs 
and requirements of our societies, as listed in Table 2.
6. Conclusions
This review supports the efficacy of telemonitoring type 1 and type 2 diabetic 
patients. Several studies on diabetes telemonitoring, using diverse technologies, 
and transmitting different clinical, medical, and behavioral data were found. 
Significant impacts were observed, namely, at the behavioral, clinical, and struc-
tural levels. Minimal technical problems and cost-effectiveness analyses were 
reported. Four studies are dedicated specifically to elderly diabetic patients (all 
including <80-year-old patients).
Close management of diabetic patients, even elderly patients, through telemoni-
toring, showed the following: improvements in control of BG level and significant 
reduction in HbA1c, better appropriation of the disease by patients, greater 
 adherence to therapeutic and hygiene-dietary measures, positive impact on comor-
bidities (arterial hypertension, weight, dyslipidemia), better patient’s quality of life, 
Overall mortality
Specific mortality of the considered chronic disease
Number of hospitalization for the considered chronic 
disease
Number of re-hospitalization for the considered 
chronic disease
Number of hospitalization days
Health costs
Management costs for the considered chronic disease
Number of days off work
Quality of life
Therapeutic education
Hygiene-dietary and therapeutic compliance
Optimization of food and sports hygiene
Patient self-management
Optimization of the care pathway for the 
considered chronic disease
Structuring of the care pathway for the considered 
chronic disease
City-hospital relations
Information sharing among health professionals
System use by health professionals
Table 2. 
Potential parameters to be evaluated in a telemedicine project for chronic disease management.
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and, at least, good receptiveness by patients and patient empowerment. Moreover, 
a cost-effectiveness analysis found a potential in medical economy. To date, the 
magnitude of its effects remains debatable, especially with the variation in patients’ 
characteristics (e.g., background, ability for self-management, medical condition), 
sample selection, and approach for treatment of control groups.
To date, relatively few projects and trials in diabetic patients have been run 
within the “telemedicine 2.0” setting, using AI, ICT, and the Web 2.0. All these 
projects include real-life elderly diabetic patients. In this setting, it is the case of the 
project DIABETe. This project, as other projects listed in this review, is perfectly 
compatible with the care pathways being developed in chronic diseases by the 
authorities of industrialized countries, such as diabetes, chronic heart failure, and 
chronic obstructive pulmonary disease.
Further investigation of telemonitoring efficacy and cost-effectiveness over 
longer periods of time and larger samples is needed. Assessment of the attitude 
of providers is also important considering their heavy workload and issues of 
reimbursement.
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